NRD
ALNY icon

Nebula Research & Development’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nebula Research & Development’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-900
Closed -$293K – 44
2025
Q2 		$293K Buy
+900
New +$249K 0.03% 795
2023
Q4 		– Sell
-2,089
Closed -$370K – 630
2023
Q3 		$370K Buy
+2,089
New +$399K 0.2% 210
2023
Q2 		– Sell
-1,162
Closed -$233K – 332
2023
Q1 		$233K Buy
+1,162
New +$244K 0.41% 149

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Nebula Research & Development's ALNY Position: Q3 2025 in Review

Nebula Research & Development sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 900 shares — an estimated $293K sold.

Nebula Research & Development first reported a position in ALNY in Q1 2023 and held it in 3 quarters. The position peaked at $370K in Q3 2023. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Nebula Research & Development reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 900 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $293K.
  • Nebula Research & Development first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Nebula Research & Development's Alnylam Pharmaceuticals position peaked at $370K in Q3 2023.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.